Clinical Trial Update: Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients. [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of autologous mesenchymal bone marrow stromal cells secreting neurotrophic factors for amyotrophic lateral sclerosis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• MSC-NTF (autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors)

Snippet

Sponsor: Brainstorm-Cell Therapeutics | Conditions: Amyotrophic Lateral Sclerosis | Phase 1, Phase 2 | Status: COMPLETED